Legal Representation
Attorney
Linda M. Byrne, Robert Crawford, Eric Curtin
USPTO Deadlines
Application History
19 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Oct 22, 2008 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Oct 22, 2008 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Mar 3, 2008 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Feb 4, 2008 | EX2G | S | EXTENSION 2 GRANTED | Loading... |
Jan 15, 2008 | EEXT | I | TEAS EXTENSION RECEIVED | Loading... |
Jan 15, 2008 | EXT2 | S | EXTENSION 2 FILED | Loading... |
Dec 3, 2007 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
May 21, 2007 | EEXT | I | TEAS EXTENSION RECEIVED | Loading... |
May 21, 2007 | EXT1 | S | EXTENSION 1 FILED | Loading... |
May 21, 2007 | EX1G | S | EXTENSION 1 GRANTED | Loading... |
Feb 20, 2007 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Nov 28, 2006 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Nov 8, 2006 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
Oct 6, 2006 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Oct 5, 2006 | ALIE | A | ASSIGNED TO LIE | Loading... |
Sep 29, 2006 | ALIE | A | ASSIGNED TO LIE | Loading... |
Sep 22, 2006 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Sep 22, 2006 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Apr 21, 2006 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for topical, intra-vaginal and/or intra-anal application, namely, pharmaceutical preparations for use in treating the skin diseases of warts, verruca vulgaris, verruca plantaris, verruca plana, flat condylomata, mosaic-type warts, butcher's warts, anogenital warts, condylomata accuminata, hyperplasia of the epidermis, recalcitrant cutaneous warts, herpes infection, genital and anal herpes infection, shingles, Molluscum contagiosum, mycosis, mycosis fungoides, tinea, tinea pedis, pigmentation disorders, hyperpigmentation, hypopigmentation, vitiligo, melasma, atypical/displastic/melanocytic nevi, sun-damaged skin, removal of tattoos, psoriasis, neurodermitis, dermatitis, atopic dermatitis, cutaneous atopy, eczema, lichen planus, cutaneous lupus erythematosus, skin ulcers, rosacea, precancerous and cancerous lesions, increased proliferation of skin cells, actinic keratosis, actinic cheilitis, keloids, lentigo, hemangioma, Epidermodysplasia verruciformis, Bowen's disease, Bowenoid papulosis, basal cell carcinoma, intraepithelial squamous cell carcinoma, melanoma, and other skin cancers, neoplasias, cervical dysplasia, cervical intraepithelial neoplasias, anal intraepithelial neoplasias, vulvar intraepithelial neoplasia, penile cancer, vulvovaginal cancer, anal carcinoma, cervical carcinoma, cutaneous T-cell lymphoma, alopecia, vulvodynia, keloid and hypertrophic scars, post surgical excision on scar cosmesis, hyperkeratosis, seborrhea, Darier's disease, porokeratosis of mibelli, ichthyosis, xerosis, dartroud disthesis, acne, nasal papilloma, oral papilloma, focal epithelial hyperplasia, laryngeal papilloma, recurrent respiratory papillomatosis and conjunctival papilloma
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005